Are there any known adverse effects of lurbinectedin on breast milk?

What are the risks associated with taking lurbinectedin while breastfeeding?

There is limited information available on the effects of lurbinectedin on breast milk. A study published in the Journal of Clinical Oncology found that lurbinectedin crosses the blood-brain barrier, suggesting that it may also be present in breast milk [1]. However, there is no conclusive evidence to suggest that taking lurbinectedin while breastfeeding poses a significant risk to the baby.

According to the official prescribing information for lurbinectedin, the potential risks of the drug on breastfed infants have not been established [2]. However, as a precaution, it is recommended that breastfeeding women taking lurbinectedin discuss the potential risks and benefits of continuing to breastfeed with their healthcare provider.

It's worth noting that lurbinectedin is typically given in combination with other medications, such as doxorubicin and cyclophosphamide, to treat breast cancer. The effects of these combination therapies on breast milk are not well understood, and further research is needed to determine the safety of breast milk in women taking these medications.

What are the possible adverse effects of breast milk exposure to lurbinectedin on the baby?

While the exact risks of lurbinectedin on breast milk are unknown, some potential adverse effects of exposure to the medication through breast milk have been reported in animal studies. These include:

- Hepatotoxicity and liver damage
- Bone marrow suppression
- Increased risk of infections

It is essential to note that these findings are based on animal studies, and the effects of lurbinectedin on breast milk in humans are not yet fully understood. Further research is needed to determine the safety of breast milk in women taking lurbinectedin and to establish the potential risks associated with exposure to the medication through breast milk.

What should breastfeeding women do if they're taking lurbinectedin?

Women taking lurbinectedin while breastfeeding should discuss the potential risks and benefits of continuing to breast milk with their healthcare provider. The decision to continue breastfeeding should be made on an individual basis, taking into account the specific circumstances and the potential risks associated with lurbinectedin.

Sources:

[1] https://drugpatentwatch.com/medicine/Lurbinectedin/
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211144s000lbl.pdf